{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T13:36:58Z","timestamp":1756993018283},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Medical Science and Technology Development Program of Shandong Province","award":["2013WS0337"],"award-info":[{"award-number":["2013WS0337"]}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"crossref","award":["ZR2010HL038"],"award-info":[{"award-number":["ZR2010HL038"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Jining Municipal Science and Technology Development Program","award":["2012jnjc16"],"award-info":[{"award-number":["2012jnjc16"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.intimp.2013.12.013","type":"journal-article","created":{"date-parts":[[2013,12,22]],"date-time":"2013-12-22T15:45:14Z","timestamp":1387727114000},"page":"213-216","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Therapeutic effect of Halofuginone on ITP mice by regulating the differentiation of Th cell subsets"],"prefix":"10.1016","volume":"18","author":[{"given":"Chengqiang","family":"Jin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanxia","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengying","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haixin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panpan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianwei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biying","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2013.12.013_bb0110","first-page":"261.e1","article-title":"Guidelines for diagnosis, treatment and monitoring of primary immune thrombocytopenia","volume":"138","author":"Sanz","year":"2012","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.intimp.2013.12.013_bb0115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1600-0609.2007.00998.x","article-title":"Epidemiology and pathophysiology of immune thrombocytopenic purpura","author":"Gernsheimer","year":"2008","journal-title":"Eur J Haematol Suppl"},{"key":"10.1016\/j.intimp.2013.12.013_bb0015","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1182\/blood.V70.4.1040.1040","article-title":"Platelet-associated and plasma anti-glycoprotein autoantibodies in chronic ITP","volume":"70","author":"McMillan","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2013.12.013_bb0020","doi-asserted-by":"crossref","first-page":"e26713","DOI":"10.1371\/journal.pone.0026713","article-title":"Halofuginone has anti-proliferative effects in acute promyelocytic leukemia by modulating the transforming growth factor beta signaling pathway","volume":"6","author":"de Figueiredo-Pontes","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2013.12.013_bb0120","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nature11774","article-title":"ATP-directed capture of bioactive herbal-based medicine on human tRNA synthetase","volume":"494","author":"Zhou","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2013.12.013_bb0030","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1593\/neo.03520","article-title":"Halofuginone inhibits angiogenesis and growth in implanted metastatic rat brain tumor model\u2013an MRI study","volume":"6","author":"Abramovitch","year":"2004","journal-title":"Neoplasia"},{"key":"10.1016\/j.intimp.2013.12.013_bb0035","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.mehy.2013.01.001","article-title":"The effect of Halofuginone in the amelioration of radiation induced-lung fibrosis","volume":"80","author":"Yavas","year":"2013","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.intimp.2013.12.013_bb0040","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1126\/science.1172638","article-title":"Halofuginone inhibits TH17 cell differentiation by activating the amino acid starvation response","volume":"324","author":"Sundrud","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.intimp.2013.12.013_bb0045","doi-asserted-by":"crossref","first-page":"e50909","DOI":"10.1371\/journal.pone.0050909","article-title":"The ratio of Treg\/Th17 cells correlates with the disease activity of primary immune thrombocytopenia","volume":"7","author":"Ji","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2013.12.013_bb0050","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2249.2010.04255.x","article-title":"Effect of immunoglobulin G (IgG) interchain disulfide bond cleavage on efficacy of intravenous immunoglobulin for immune thrombocytopenic purpura (ITP)","volume":"162","author":"Machino","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.intimp.2013.12.013_bb0055","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/blood.V98.4.1095","article-title":"Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia","volume":"98","author":"Teeling","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2013.12.013_bb0060","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/sji.12048","article-title":"Antioxidant status and oxidative stress in patients with chronic ITP","volume":"77","author":"Jin","year":"2013","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.intimp.2013.12.013_bb0125","first-page":"96","article-title":"The changes and clinical significance of CD62P,PAIgG,Tr cell in children with acute idiopathic thrombocytopenic purpura patients","volume":"38","author":"Jin CQ Dong","year":"2011","journal-title":"Int. J. Pediatr. (China)"},{"key":"10.1016\/j.intimp.2013.12.013_bb0070","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1053\/tmrv.2003.50004","article-title":"Cellular immune mechanisms in autoimmune thrombocytopenic purpura: an update","volume":"17","author":"Coopamah","year":"2003","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.intimp.2013.12.013_bb0075","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1179\/1607845412Y.0000000011","article-title":"Chronic immune thrombocytopenic purpura in childhood: pathogenetic mechanisms and management","volume":"17","author":"Ferrara","year":"2012","journal-title":"Hematology"},{"key":"10.1016\/j.intimp.2013.12.013_bb0080","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1159\/000335553","article-title":"Platelet kinetics in idiopathic thrombocytopenic purpura patients treated with thrombopoietin receptor agonists","volume":"39","author":"Meyer","year":"2012","journal-title":"Transfus Med Hemother"},{"key":"10.1016\/j.intimp.2013.12.013_bb0085","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1634\/theoncologist.2008-0132","article-title":"Chronic idiopathic thrombocytopenic purpura: mechanisms of pathogenesis","volume":"14","author":"Gernsheimer","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.intimp.2013.12.013_bb0090","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.intimp.2013.04.031","article-title":"Halofuginone suppresses T cell proliferation by blocking proline uptake and inducing cell apoptosis","volume":"16","author":"Chu","year":"2013","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.intimp.2013.12.013_bb0095","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1751-553X.2011.01375.x","article-title":"Type 2 polarized immune response holds a major position in Epstein-Barr virus-related idiopathic thrombocytopenic purpura (EBV-ITP)","volume":"34","author":"Jin","year":"2012","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.intimp.2013.12.013_bb0130","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1074-7613(03)00057-8","article-title":"GATA-3 suppresses Th1 development by downregulation of Stat4 and not through effects on IL-12Rbeta2 chain or T-bet","volume":"18","author":"Usui","year":"2003","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2013.12.013_bb0105","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S1074-7613(00)80671-8","article-title":"Inhibition of Th1 development mediated by GATA-3 through an IL-4-independent mechanism","volume":"9","author":"Ouyang","year":"1998","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2013.12.013_bb0135","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0092-8674(00)80702-3","article-title":"A novel transcription factor, T-bet, directs Th1 lineage commitment","volume":"100","author":"Szabo","year":"2000","journal-title":"Cell"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576913005006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576913005006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T19:40:26Z","timestamp":1597261226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576913005006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S1567576913005006"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2013.12.013","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic effect of Halofuginone on ITP mice by regulating the differentiation of Th cell subsets","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2013.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}